当前位置: 首页 > 期刊 > 《医学信息》 > 20202
编号:13516474
老年社区获得性肺炎并脓毒症患者sCD14和CD14+/HLA-DR表达及意义(4)
http://www.100md.com 2020年1月15日 《医学信息》 20202
     [7]中华医学会呼吸病学分会.中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J].中华结核和呼吸杂志,2016,4(39):1-27.

    [8]Singer M,Deutschman CS,Seymour CW,et al.The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)[J].The Journal of the American Medical Association,2016, 315(8):775-787.

    [9]赖丽仁.新型脓毒症生物标志物Presepsin(sCD14-亚型)的研究进展[J].中华重症医学电子杂志,2017, 3(3):178-181.

    [10]Yaegashi Y,Shirakawa K,Sato N,et al.Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis[J].Journal of Infection&Chemotherapy,2005,11(5):234-238.

    [11]Kitchens RL,Thompson PA,Viriyakosol S,et al.Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins[J].Journal of Clinical Investigation, 2001,108(3):485-493.

    [12]Masson S,Caironi P,Fanizza C,et al.Erratum to:Circulating presepsin(soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock:data from the multicenter,randomized ALBIOS trial[J].Intensive Care Medicine,2014,41(1):12-20.

    [13]Lekkou A,Karakantza M,Mouzaki A,et al.Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections[J].Clin Diagn Lab Immunol,2004,11(1):161-167.

    [14]蘇磊,周殿元,唐柚青,等.CD14+单核细胞人白细胞DR抗原在脓毒症早期检测中的临床意义[J].中华危重病急救医学,2006,18(11):677-679.

    收稿日期:2019-10-13;修回日期:2019-11-08

    编辑/肖婷婷, 百拇医药(石玉英 段训新 黄龙)
上一页1 2 3 4